| Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects F Holze, P Vizeli, F Müller, L Ley, R Duerig, N Varghese, A Eckert, ... Neuropsychopharmacology 45 (3), 462-471, 2020 | 192 | 2020 |
| Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects F Holze, P Vizeli, L Ley, F Müller, P Dolder, M Stocker, U Duthaler, ... Neuropsychopharmacology 46 (3), 537-544, 2021 | 163 | 2021 |
| Safety pharmacology of acute MDMA administration in healthy subjects P Vizeli, ME Liechti Journal of Psychopharmacology 31 (5), 576-588, 2017 | 149 | 2017 |
| Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects F Holze, L Ley, F Müller, AM Becker, I Straumann, P Vizeli, SS Kuehne, ... Neuropsychopharmacology 47 (6), 1180-1187, 2022 | 94 | 2022 |
| Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects F Holze, U Duthaler, P Vizeli, F Müller, S Borgwardt, ME Liechti British journal of clinical pharmacology 85 (7), 1474-1483, 2019 | 72 | 2019 |
| CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3, 4-methylene-dioxymethamphetamine in a controlled study in healthy individuals Y Schmid, P Vizeli, CM Hysek, K Prestin, HEM Zu Schwabedissen, ... Pharmacogenetics and genomics 26 (8), 397-401, 2016 | 48 | 2016 |
| Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects PC Dolder, P Strajhar, P Vizeli, F Hammann, A Odermatt, ME Liechti Frontiers in pharmacology 8, 289246, 2017 | 45 | 2017 |
| Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects P Vizeli, Y Schmid, K Prestin, HEM Zu Schwabedissen, ME Liechti European Neuropsychopharmacology 27 (3), 232-238, 2017 | 45 | 2017 |
| Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects P Vizeli, ME Liechti PLoS One 13 (6), e0199384, 2018 | 41 | 2018 |
| Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies E Studerus, P Vizeli, S Harder, L Ley, ME Liechti Journal of Psychopharmacology 35 (5), 556-565, 2021 | 33 | 2021 |
| Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants F Müller, E Kraus, F Holze, A Becker, L Ley, Y Schmid, P Vizeli, ME Liechti, ... Psychopharmacology 239 (6), 1933-1943, 2022 | 32 | 2022 |
| Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects PC Dolder, P Strajhar, P Vizeli, A Odermatt, ME Liechti Psychopharmacology 235, 1389-1402, 2018 | 27 | 2018 |
| MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens F Müller, F Holze, P Dolder, L Ley, P Vizeli, A Soltermann, ME Liechti, ... Neuropsychopharmacology 46 (3), 545-553, 2021 | 26 | 2021 |
| Safety pharmacology of acute LSD administration in healthy subjects F Holze, TV Caluori, P Vizeli, ME Liechti Psychopharmacology, 1-13, 2022 | 25 | 2022 |
| Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis P Vizeli, I Straumann, F Holze, Y Schmid, PC Dolder, ME Liechti Scientific reports 11 (1), 10851, 2021 | 25 | 2021 |
| Comparative untargeted metabolomics analysis of the psychostimulants 3, 4-methylenedioxy-methamphetamine (MDMA), amphetamine, and the novel psychoactive substance mephedrone … AE Steuer, D Kaelin, MI Boxler, L Eisenbeiss, F Holze, P Vizeli, ... Metabolites 10 (8), 306, 2020 | 25 | 2020 |
| Characterizing thalamocortical (dys) connectivity following d-amphetamine, LSD, and MDMA administration M Avram, F Müller, H Rogg, A Korda, C Andreou, F Holze, P Vizeli, L Ley, ... Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 7 (9), 885-894, 2022 | 23 | 2022 |
| Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects P Vizeli, HE Meyer Zu Schwabedissen, ME Liechti ACS chemical neuroscience 10 (7), 3120-3131, 2018 | 17 | 2018 |
| No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA P Vizeli, HE Meyer zu Schwabedissen, ME Liechti European journal of clinical pharmacology 74, 275-283, 2018 | 17 | 2018 |
| Effects of 3, 4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects P Vizeli, I Straumann, U Duthaler, N Varghese, A Eckert, MP Paulus, ... Frontiers in Pharmacology 13, 906639, 2022 | 16 | 2022 |
Matthias LiechtiUniversity Hospital BaselVerified email at usb.ch
